Novo nordisk a articles
-
Motley Fool Wealth Management LLC Lowers Position in Novo Nordisk A/S (NYSE:NVO)
Motley Fool Wealth Management LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 192,468 shares of the company’s stock after selling 2,372 shares during the period. Novo […]
-
Weight-loss drug startup Metsera wants to take on Novo and Lilly. Here's what you need to know
Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss treatments that it hopes to bring to market. The company, which has already acquired the U.K.-based startup, Zihipp, and formed a licensing pact with a South Korean drugmaker, D&D Pharmatech, claims that its products could eventually compete with industry leaders Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro....